Compounded vs Brand Semaglutide

Compounded semaglutide is semaglutide prepared by a compounding pharmacy — either a state-licensed 503A pharmacy that makes individual patient prescriptions, or a 503B outsourcing facility that makes larger batches under some FDA oversight. It is not an FDA-approved finished drug product. Compounded semaglutide is only permitted while the FDA has declared the brand version to be in shortage.

The active ingredient — semaglutide — is chemically the same molecule. But compounded formulations often include additives such as vitamin B12 or glycine, come in different concentrations, arrive as multi-dose vials rather than pre-filled pens, and are not held to the batch-testing and manufacturing standards that FDA-approved finished drugs must meet. Clinically, response is expected to be similar when potency is accurate, but potency is exactly what varies between compounding sources.

Roughly $150–$400 a month versus $1,000+ for the brand — that gap exists because compounded semaglutide is not subject to the pricing, marketing, and clinical development costs that finished-drug manufacturers carry, and it does not go through the FDA approval pathway. It is also usually paid out-of-pocket rather than routed through insurance and pharmacy benefit managers.

The molecule is the same, but the finished product is not. Reported risks include sub-potent lots, mislabelled concentrations, contamination, and dosing errors when patients draw from vials with an insulin syringe. The FDA has publicly warned about compounded GLP-1 products and reported adverse events. If you use compounded, source it from a licensed US pharmacy (503A/503B) that publishes independent lab testing, and confirm concentration on the vial before every dose.

Only while the FDA lists semaglutide as being in shortage. When the shortage designation is resolved, most compounding of semaglutide becomes prohibited except in narrow clinical scenarios (allergy to a brand excipient, unique dose not commercially available). The FDA has declared Wegovy off shortage in 2025; the practical rules for compounders continue to evolve.

Compounded semaglutide is usually supplied in a multi-dose vial at a concentration in mg/mL. You draw your prescribed dose in mL using a U-100 insulin syringe, where 1 mL equals 100 units. The Calqulate GLP-1 Dose Calculator does the mg-to-units math for you, but always verify with your prescribing pharmacy — a small labelling difference can double or halve your actual dose.

There is no universal answer. Brand semaglutide (Wegovy or Ozempic) is FDA-approved, has trial-verified potency, may be partly covered by insurance, and carries the safety data from STEP, SUSTAIN, and SELECT. Compounded is cheaper and allows more flexible dose steps, but the finished product is not FDA-reviewed and quality depends on the pharmacy. Discuss both with your prescriber and factor in cost, coverage, and your tolerance for regulatory ambiguity.